FAILED
首站-论文投稿智能助手
典型文献
JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKK β
文献摘要:
Objective: Multiple myeloma (MM) remains incurable with high rates of relapse. New therapeutic drugs are therefore urgently needed to improve the prognosis. JaponiconeA (JA), a natural product isolated from Inula japonica Thunb, has shown good anti-MM potential. A comprehensive study should therefore be conducted to identify both the in vitro and in vivo mechanisms of the anti-MM effects of JA. Methods: CCK8 assays and flow cytometry were used to detect the proliferation, apoptosis, and cell cycle of MM cell lines when treated with JA. In vivo experiments were conducted using subcutaneous xenograft mouse models. We also identified possible targets and the mechanism of JA using RNA-seq and c-Map databases, and identified the specific targets of JA in bortezomib-sensitive and -resistant MM cell lines using CETSA, DARTS, and rescue experiments. Furthermore, JA and bortezomib were used separately or together to characterize their possible synergistic effects. Results: In vitro, JA inhibited proliferation, and induced apoptosis and G2/M phase arrest in MM cell lines, and selectively killed primary CD138+ MM cells. In vivo, JA also demonstrated a strong anti-tumor effect with no observable toxicity. In addition, JA showed synergetic effects in combination with bortezomib, and enhanced the anti-tumor effect of bortezomib in bortezomib-resistant cells. CETSA and DARTS confirmed direct binding of JA to NF-κB inhibitor kinase beta (IKKβ), and overexpression of IKKβ or knockdown of IκBα partially rescued the apoptosis induced by JA. Conclusions: JA exhibited strong anti-tumor effects in MM. It sensitized myeloma cells to bortezomib and overcame NF-κB-induced drug resistance by inhibiting IKKβ, providing a new treatment strategy for MM patients.
文献关键词:
作者姓名:
Zilu Zhang;Chenjing Ye;Jia Liu;Wenbin Xu;Chao Wu;Qing Yu;Xiaoguang Xu;Xinyi Zeng;Huizi Jin;Yingli Wu;Hua Yan
作者机构:
Shanghai Institute of Hematology,Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;VIP Health Center,Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs,School of Pharmacy,Shanghai Jiao Tong University,Shanghai 200240,China;Hongqiao International Institute of Medicine,Shanghai Tongren Hospital/Faculty of Basic Medicine,Chemical Biology Division of Shanghai Universities E-Institutes,Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
引用格式:
[1]Zilu Zhang;Chenjing Ye;Jia Liu;Wenbin Xu;Chao Wu;Qing Yu;Xiaoguang Xu;Xinyi Zeng;Huizi Jin;Yingli Wu;Hua Yan-.JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKK β)[J].癌症生物学与医学(英文版),2022(05):651-668
A类:
JaponiconeA
B类:
induces,apoptosis,bortezomib,sensitive,resistant,myeloma,cells,vitro,vivo,by,targeting,IKK,Objective,Multiple,MM,remains,incurable,high,rates,relapse,New,therapeutic,drugs,are,therefore,urgently,needed,improve,prognosis,JA,natural,product,isolated,from,Inula,japonica,Thunb,shown,good,anti,potential,comprehensive,study,should,conducted,identify,both,mechanisms,effects,Methods,CCK8,assays,flow,cytometry,were,used,detect,proliferation,cycle,lines,when,treated,experiments,using,subcutaneous,xenograft,mouse,models,We,also,identified,possible,targets,seq,Map,databases,specific,CETSA,DARTS,Furthermore,separately,together,characterize,their,synergistic,Results,inhibited,induced,G2,phase,arrest,selectively,killed,primary,CD138+,demonstrated,strong,tumor,observable,toxicity,addition,showed,synergetic,combination,enhanced,confirmed,direct,binding,inhibitor,kinase,beta,overexpression,knockdown,partially,rescued,Conclusions,exhibited,It,sensitized,overcame,resistance,inhibiting,providing,new,treatment,strategy,patients
AB值:
0.516665
相似文献
Paired box 5 increases the chemosensitivity of esophageal squamous cell cancer cells by promoting p53 signaling activity
Zhang Weiwei;Yan Wenji;Qian Niansong;Han Quanli;Zhang Weitao;Dai Guanghai-Chinese People’s Liberation Army Medical School, Beijing 100853, China;Department of the Third Health Care, The Second Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100853, China;Department of Oncology, The First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100853, China;Department of Oncology, The Hainan Medical Center, Chinese People’s Liberation Army General Hospital, Sanya 572022, China;Cancer Center, Beijing Tongren Hospital Affiliated to Capital Medical University, Economic and Technological Development Zone, Beijing 100176, China
NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma
Rongfang Wei;Xing Cui;Jie Min;Zigen Lin;Yanyan Zhou;Mengjie Guo;Xiaojuan An;Hao Liu;Siegfried Janz;Chunyan Gu;Hongbo Wang;Ye Yang-Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Nanjing 210022,China;School of Medicine&Holistic Integrative Medicine,Nanjing University of Chinese Medicine,Nanjing 210023,China;Department of Hematology,Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250014,China;Division of Hematology and Oncology,Medical College of Wisconsin,Milwaukee,WI 53226,USA;School of Pharmacy,Key Laboratory of Molecular Pharmacology and Drug Evaluation(Yantai University),Ministry of Education,Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong,Yantai University,Yantai 264005,China;Bohai Rim Advanced Research Institute for Drug Discovery,Yantai 264003,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
Pharmacodynamic,pharmacokinetic,and phase 1a study of bisthianostat,a novel histone deacetylase inhibitor,for the treatment of relapsed or refractory multiple myeloma
Yu-bo Zhou;Yang-ming Zhang;Hong-hui Huang;Li-jing Shen;Xiao-feng Han;Xiao-bei Hu;Song-da Yu;An-hui Gao;Li Sheng;Ming-bo Su;Xiao-li Wei;Yue Zhang;Yi-fan Zhang;Zhi-wei Gao;Xiao-yan Chen;Fa-jun Nan;Jia Li;Jian Hou-National Center for New Drug Screening,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Yantai Key Laboratory of Nanomedicine&Advanced Preparations,Yantai Institute of Materia Medica,Yantai 264000,China;Department of Hematology,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200127,China;Shanghai Center for Drug Metabolism and Pharmacokinetics Research,Shanghai 201203,China
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。